IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
March 13, 2025 16:05 ET
|
IN8bio, Inc
IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights
IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases
March 03, 2025 09:28 ET
|
IN8bio, Inc
Proprietary platform represents the first known approach capable of sustained γδ T cell expansion, eliminating target cells with robust potencyINB-619, a next generation γδ TCE targeting CD19,...
IN8bio to Present at the TD Cowen 45th Annual Health Care Conference
February 26, 2025 08:00 ET
|
IN8bio, Inc
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that...
IN8bio to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
February 24, 2025 08:00 ET
|
IN8bio, Inc
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that...
IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML
February 14, 2025 09:00 ET
|
IN8bio, Inc
IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Strong Durability of Remissions in High-Risk AML
IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients
February 11, 2025 08:00 ET
|
IN8bio, Inc
IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients
IN8bio to Present at Biotech Showcase 2025 in San Francisco
January 06, 2025 07:00 ET
|
IN8bio, Inc
NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced William Ho,...
IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting
December 10, 2024 07:00 ET
|
IN8bio, Inc
IN8bio Reports Continued Progression-Free Survival in Phase 1 Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 ASH Conference
IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference
December 02, 2024 07:00 ET
|
IN8bio, Inc
NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that William...
IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting
November 25, 2024 07:00 ET
|
IN8bio, Inc
IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting